RUNX1 and acute myeloid leukemia: To evaluate the efficacy of avatinib plus allogeneic hematopoietic stem cell transplantation(allo-HSCT)for the treatment of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia(AML)with KIT mutations.